Allergen-specific intralymphatic immunotherapy in human and animal studies

Clinical trials of intralymphatic immunotherapy (ILIT) have been performed to overcome the limitations of long-term therapy and the local or systemic hypersensitivity reactions in conventional allergen-specific immunotherapy, including subcutaneous or sublingual immunotherapy. Additionally, several...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Seon Tae, Park, So Hyun, Lee, Sang Min, Lee, Sang Pyo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Asia Pacific Association of Allergy, Asthma and Clinical Immunology 2017
Materias:
Current Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5537077/
https://www.ncbi.nlm.nih.gov/pubmed/28765817
http://dx.doi.org/10.5415/apallergy.2017.7.3.131
Descripción
Sumario:Clinical trials of intralymphatic immunotherapy (ILIT) have been performed to overcome the limitations of long-term therapy and the local or systemic hypersensitivity reactions in conventional allergen-specific immunotherapy, including subcutaneous or sublingual immunotherapy. Additionally, several animal studies of ILIT have been conducted in the form of translational or veterinary research. We conducted a literature review to examine the treatment efficacy and adverse effects of ILIT.

Ejemplares similares